> 首页 > 产品 > 一抗 > 基因重组 > Anti-IL-18 Reference Antibody (Camoteskimab)

Anti-IL-18 Reference Antibody (Camoteskimab)

Recombinant Antibody

Anti-IL-18 Reference Antibody (Camoteskimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%
The purity of Anti-IL-18 Reference Antibody (Camoteskimab)is more than 98.41% ,determined by SEC-HPLC.
Immobilized human IL 18 C His at 2 µg/mL can bind Anti-IL-18 Reference Antibody (Camoteskimab)，EC50=0.0126 µg/mL
Anti-IL-18 Reference Antibody (Camoteskimab)-induced FACS Blocking activity was evaluated using Hu IL-18Rα&IL-18Rβ HEK293-. The IC50 was approximately 0.172 µg/mL .

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	FC, Kinetics, Animal Model
Primary Accession	Q14116
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	22326 Da

Additional Information
Target/Specificity	IL-18
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information
Name	IL18 (HGNC:5986)
Synonyms	IGIF, IL1F4
Function	Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed:10653850). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed:14528293, PubMed:25500532, PubMed:37993714). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed:10653850). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744).
Cellular Location	Cytoplasm, cytosol. Secreted. Note=The precursor is cytosolic (PubMed:33883744). In response to inflammasome-activating signals, cleaved and secreted (PubMed:33883744, PubMed:37993712, PubMed:37993714). Mature form is secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744, PubMed:37993714). In contrast, the precursor form is not released, due to the presence of an acidic region that is proteolytically removed by CASP1, CASP4 or CASP5 during maturation (PubMed:33883744, PubMed:37993714). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10 (PubMed:32272059).
Tissue Location	[Isoform 2]: Expressed in ovarian carcinoma but undetectable in normal ovarian epithelial cells. Resistant to proteolytic activation by caspase-1 and -4